WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 206120
Description: Chiauranib also known as orally available, small molecule inhibitor of select serine-threonine kinases, including aurora kinase B (aurora B), vascular endothelial growth factor receptors (VEGFRs), stem cell factor receptor (c-KIT), and platelet-derived growth factor receptors (PDGFRs), with potential antineoplastic activity. Upon oral administration, chiauranib binds to and inhibits the activity of aurora B, VEGFRs, c-kit and PDGFRs, which may result in a decrease in the proliferation of tumor cells that overexpress these kinases. These kinases are overexpressed by a variety of cancer cell types.
MedKoo Cat#: 206120
Chemical Formula: C27H21N3O3
Exact Mass: 435.1583
Molecular Weight: 435.483
Elemental Analysis: C, 74.47; H, 4.86; N, 9.65; O, 11.02
Chiauranib, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
Synonym: Chiauranib; CS2164; CS-2164; CS 2164.
IUPAC/Chemical Name: N-(2-aminophenyl)-6-((7-methoxyquinolin-4-yl)oxy)-1-naphthamide
InChi Key: BRKWREZNORONDU-UHFFFAOYSA-N
InChi Code: InChI=1S/C27H21N3O3/c1-32-18-9-12-22-25(16-18)29-14-13-26(22)33-19-10-11-20-17(15-19)5-4-6-21(20)27(31)30-24-8-3-2-7-23(24)28/h2-16H,28H2,1H3,(H,30,31)
SMILES Code: O=C(C1=C2C=CC(OC3=CC=NC4=CC(OC)=CC=C43)=CC2=CC=C1)NC5=CC=CC=C5N
The following data is based on the product molecular weight 435.483 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Deng M, Shi Y, Chen K, Zhao H, Wang Y, Xie S, Zhao J, Luo Y, Fang Z, Fan Y, Xu
B. CS2164 exerts an antitumor effect against human Non-Hodgkin's lymphomas in
vitro and in vivo. Exp Cell Res. 2018 Aug 15;369(2):356-362. doi:
10.1016/j.yexcr.2018.05.038. Epub 2018 Jun 1. PubMed PMID: 29864401.
2: Zhou Y, Shan S, Li ZB, Xin LJ, Pan DS, Yang QJ, Liu YP, Yue XP, Liu XR, Gao
JZ, Zhang JW, Ning ZQ, Lu XP. CS2164, a novel multi-target inhibitor against
tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency.
Cancer Sci. 2017 Mar;108(3):469-477. doi: 10.1111/cas.13141. Epub 2017 Mar 7.
PubMed PMID: 28004478; PubMed Central PMCID: PMC5378272.